Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

Healthcare Biotechnology
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.


NDAQ:IPA - Post by User

Immunoprecise Antibodies Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(22)
•••
Post by wallpaper2on Oct 25, 2023 10:23am
294 Views
Post# 35699953

Todays game changing news release.

Todays game changing news release.There are many many AI upstart companies out there,  but none can touch what Biostrand/Hyft now offer.  IPA described their $25 million purchase of Biostrand as "The Aquisition of the CENTURY." Coupled with their patented world best Hyft Platform they will be rolling out this game changing Best in Class technology in January 2024. Read todays news and see how this will revolutionize Drug Discovery in SEVERAL  ways. IPA has the trchnology,  a new strong Board of Directors from N.America and Europe, a partnership with the Worlds #1 Health Bank and multiple Investment Funds. IPA will be introduced to the world in 2024 and may become the years top success story. Cheers

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities